863132-19-8

Basic information

• Product Name: N-{2-[2-(3,4-dimethoxy-phenylethynyl)-4,5-dimethoxy-phenyl]-ethyl}-2,2,2-trifluoro-acetamide
• Synonyms: N-{2-[2-(3,4-dimethoxy-phenylethynyl)-4,5-dimethoxy-phenyl]-ethyl}-2,2,2-trifluoro-acetamide
• CAS NO: 863132-19-8
• Molecular Weight: 437.416
• Mol File: 863132-19-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-{2-[2-(3,4-dimethoxy-phenylethynyl)-4,5-dimethoxy-phenyl]-ethyl}-2,2,2-trifluoro-acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-{2-[2-(3,4-dimethoxy-phenylethynyl)-4,5-dimethoxy-phenyl]-ethyl}-2,2,2-trifluoro-acetamide(863132-19-8)
• EPA Substance Registry System: N-{2-[2-(3,4-dimethoxy-phenylethynyl)-4,5-dimethoxy-phenyl]-ethyl}-2,2,2-trifluoro-acetamide(863132-19-8)

Safety Data

• Hazardous Substances Data: 863132-19-8(Hazardous Substances Data)

Upstream product

• 13230-71-2 N-[2-(3,4-dimethoxyphenyl)ethyl]-2,2,2-trifluoroacetamide 
• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 5460-32-2 1-iodo-3,4-dimethoxybenzene 
• 91-16-7 1,2-dimethoxybenzene 
• 863132-17-6 (3,4-dimethoxy-phenylethynyl)-trimethyl-silane 
• 4302-52-7 4-ethynylveratrole 
• 154138-43-9 2,2,2-trifluoro-N-<2-(2-iodo-4,5-dimethoxyphenyl)ethyl>acetamide 

Downstream Products

• 85-63-2 (R)-laudanosine 
• 2688-77-9 (S)-laudanosine 
• 523-02-4 (S)-(-)-norcoralydine 
• 4747-98-2 S-(-)-Norlaudanosine 
• 50896-90-7 (-) N-norlaudanosine 
• 6872-27-1 (R)-(+)-xylopinine 
• 6957-27-3 3,4-dihydropapaverine 
• 863132-09-6 2-[2-(3,4-dimethoxy-phenylethynyl)-4,5-dimethoxy-phenyl]-ethylamine 

Relevant articles and documents

Enantioselective synthesis of (+)-(S)-laudanosine and (-)-(S)-xylopinine

The study presents a new pathway for the enantioselective synthesis of benzylisoquinoline alkaloids. The key steps of the synthesis of (+)-(S)-laudanosine (1) and (-)-(S)-xylopinine (2) are a Sonogashira coupling that builds up the C1-C8a bond of the benzylisoquinoline skeleton, an intramolecular Ti-catalyzed hydroamination of an alkyne, and a subsequent enantioselective imine reduction according to Noyori's protocol.